Goodman Marc T, Hernandez Brenda Y, Hewitt Stephen, Lynch Charles F, Coté Timothy R, Frierson Henry F, Moskaluk Christopher A, Killeen Jeffrey L, Cozen Wendy, Key Charles R, Clegg Limin, Reichman Marsha, Hankey Benjamin F, Edwards Brenda
Etiology Program, Hawaii Tumor Registry, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI 96813, USA.
Hum Pathol. 2005 Jul;36(7):812-20. doi: 10.1016/j.humpath.2005.03.010.
Population-based cancer registries, such as those included in the Surveillance, Epidemiology, and End-Results (SEER) Program, offer tremendous research potential beyond traditional surveillance activities. We describe the expansion of SEER registries to gather formalin-fixed, paraffin-embedded tissue from cancer patients on a population basis. Population-based tissue banks have the advantage of providing an unbiased sampling frame for evaluating the public health impact of genes or protein targets that may be used for therapeutic or diagnostic purposes in defined communities. Such repositories provide a unique resource for testing new molecular classification schemes for cancer, validating new biologic markers of malignancy, prognosis and progression, assessing therapeutic targets, and measuring allele frequencies of cancer-associated genetic polymorphisms or germline mutations in representative samples. The assembly of tissue microarrays will allow for the use of rapid, large-scale protein-expression profiling of tumor samples while limiting depletion of this valuable resource. Access to biologic specimens through SEER registries will provide researchers with demographic, clinical, and risk factor information on cancer patients with assured data quality and completeness. Clinical outcome data, such as disease-free survival, can be correlated with previously validated prognostic markers. Furthermore, the anonymity of the study subject can be protected through rigorous standards of confidentiality. SEER-based tissue resources represent a step forward in true, population-based tissue repositories of tumors from US patients and may serve as a foundation for molecular epidemiology studies of cancer in this country.
基于人群的癌症登记处，例如监测、流行病学和最终结果（SEER）计划中包含的那些登记处，除了传统的监测活动外，还具有巨大的研究潜力。我们描述了SEER登记处的扩展，以在人群基础上从癌症患者中收集福尔马林固定、石蜡包埋的组织。基于人群的组织库具有提供无偏抽样框架的优势，可用于评估在特定社区中可能用于治疗或诊断目的的基因或蛋白质靶点对公共卫生的影响。此类储存库为测试新的癌症分子分类方案、验证新的恶性肿瘤、预后和进展的生物学标志物、评估治疗靶点以及测量代表性样本中癌症相关基因多态性或种系突变的等位基因频率提供了独特的资源。组织微阵列的组装将允许在限制这种宝贵资源消耗的同时，对肿瘤样本进行快速、大规模的蛋白质表达谱分析。通过SEER登记处获取生物标本将为研究人员提供有关癌症患者的人口统计学、临床和危险因素信息，确保数据质量和完整性。临床结局数据，如无病生存期，可以与先前验证的预后标志物相关联。此外，通过严格的保密标准可以保护研究对象的匿名性。基于SEER的组织资源代表了美国患者真实的、基于人群的肿瘤组织储存库向前迈出的一步，并可能成为该国癌症分子流行病学研究的基础。
